醫藥股普遍回吐 來凱(02105.HK)及藥明合聯(02268.HK)跌逾半成 惟科倫博泰(06990.HK)創上市新高
恆指繼昨天反彈受制16,500後,今天反覆回軟,現報16,290,反覆回吐11點,總成交額496億元。
醫藥股今天普遍回吐,尤其是來凱醫藥-B(02105.HK)今天股價曾挫11%至12.44元創逾三個月低,現報13.3元,回吐5.1%。
藥明合聯(02268.HK)扭兩連升,股價低見30.8元,現報30.95元,回吐5.4%;藥明生物(02269.HK)繼昨天急漲至33.4元無以為繼升幅明顯收窄後,今天股價反覆回吐3.1%報29.5元。中生製藥(01177.HK)股價曾挫5.4%至3.14元,現報3.25元,續跌2.1%。
藍籌國藥(01099.HK)、聯邦制藥(03933.HK)、金斯瑞(01548.HK)、信達生物(01801.HK)、康方生物(09926.HK)、康龍化成(03759.HK)、君實生物(01877.HK)、宜明昂科-B(01541.HK)、凱萊英(06821.HK)、中國中藥(00570.HK)、康龍化成(03759.HK)、再鼎醫藥(09688.HK)、艾美疫苗(06660.HK)、三葉草生物-B(02197.HK)、康寧傑瑞製藥-B(09966.HK)、榮昌生物(09995.HK)及雲頂新耀-B(01952.HK)跌約2%-4%。
醫療器械股則以康灃生物-B(06922.HK)表現最差,股價續挫10%報14.82元即市低位。復銳醫療科技(01696.HK)回吐4.2%報5.19元。
然而,去年7月才以每股60.6元上市的科倫博泰生物-B(06990.HK)連升第四天,今天股價反覆升破上月所創上市高位108元,最高見109.3元,現報108.8元,升2.2%。昨天逆挫的藍籌石藥(01093.HK)反覆回升1.7%報6.58元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.